CONGRESS COVERAGE: EHA 2020 – FOCUS ON LEUKEMIA AND MDS

Clinical trials updates, emerging therapies, and future directions in acute lymphoblastic leukemia (ALL), myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML)

June 15, 2020
Dieter Hoelzer, MD, PhD Aptitude Health EPICS Leukemia

FACULTY CO-CHAIR

Dieter Hoelzer, MD, PhD

University of Frankfurt, Frankfurt, Germany

FACULTY CO-CHAIR

Elias Jabbour, MD

University of Texas MD Anderson Cancer Center, Houston, TX, USA

Faculty Members

Daniel DeAngelo, MD, PhD
Dana-Farber Cancer Institute, Boston, MA, US

Naval Daver, MD
University of Texas MD Anderson Cancer Center, Houston, TX, US

Gert Ossenkoppele, MD, PhD
VU Medical Center, Amsterdam, The Netherlands

Josep-Maria Ribera, MD, PhD
Hospital Universitari Germans Trias i Pujol, Barcelona, Spain

Valeria Santini, MD
University of Florence, Florence, Italy

Jorge Sierra, MD, PhD
Hospital de la Santa Creu I Sant Pau, Barcelona, Spain

Sample Report

Start discovering the insights

View Report

REPORT TOPICS INCLUDE

  • MDS
  • Elderly/Unfit AML Patients
  • IDH– and FLT3-Mutant AML Patients
  • Emerging Immune Therapies in AML
  • Updates in ALL
  • Strategic Insights and Key Takeaways

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.